| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -4.9 | -3.9 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: QNRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Quoin Pharmaceuticals Ltd.: key numbers
- Share price
- $3.56Close, Nov 16
- Market cap
- $250M
- Shares outstanding
- 70.29MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Quoin Pharmaceuticals Ltd.
All →Quoin Pharmaceuticals Other 8-K Filing
Shareholders of Quoin Pharmaceuticals approved a proposal to amend beneficial ownership limitations for investors from previous private placements. The amendment allows investors to increase their ownership cap from 4.99% to up to 9.99% of outstanding ordinary shares upon written notice. This change applies to transactions consummated in October 2025 and August 2026 and aligns with both US and Israeli securities laws.
Quoin Pharmaceuticals Financial Results
Quoin Pharmaceuticals reported third quarter 2026 financial results and provided a corporate update, including positive interim Phase 2/3 data for QRX003 in Netherton Syndrome. The company also highlighted a private placement financing of up to $50.0 million to fund the completion of QRX003 development. Topline data for the Netherton Syndrome study is expected in Q2 2027.
“The third quarter substantially strengthened Quoin’s clinical, regulatory and financial foundation for long-term growth. Interim clinical results from our Phase 2/3 study of QRX003 in Netherton Syndrome demonstrated statistical significance for the primary and key secondary endpoints, representing what we believe is the first ever overall positive data set published for this disease.”
Dr. Michael Myers, Chief Executive Officer and Co-Founder
“Our priorities for the coming months are very clear. We expect to complete recruitment in our Netherton Syndrome study by year end and report topline data in the second quarter of 2027.”
Dr. Michael Myers, Chief Executive Officer and Co-Founder
Quoin Pharmaceuticals Capital Raise
Quoin Pharmaceuticals entered into an at-the-market (ATM) sales agreement with Leerink Partners LLC to sell American Depositary Shares (ADSs) from time to time. Leerink Partners will act as the sales agent and receive a 3.0% commission on gross proceeds from any sales made under the program.
- Counterparty
- Leerink Partners LLC
Quoin Pharmaceuticals Clinical Trial Data
Quoin Pharmaceuticals announced the publication of a peer-reviewed case report detailing 21 months of compassionate use treatment with QRX003 in a pediatric Netherton Syndrome patient, showing an improvement from severe to clear skin. The company also reaffirmed that its ongoing Phase 2/3 study of QRX003 expects to complete recruitment by the end of 2026 with topline data anticipated in Q2 2027.
- Term
- 21 months
Quoin Pharmaceuticals Other 8-K Filing
Quoin Pharmaceuticals announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its lead product candidate, QRX003, for the treatment of Peeling Skin Syndrome. This designation provides 10 years of market exclusivity in Europe upon potential marketing authorization and follows similar regulatory milestones in the US and Japan. The company remains on track to initiate the first-ever formal clinical study for Peeling Skin Syndrome before the end of 2026.
- Counterparty
- European Medicines Agency
Quoin Pharmaceuticals Regulatory Approval
Quoin Pharmaceuticals announced that the FDA has granted Fast Track Designation to its lead asset, QRX003, for the treatment of Peeling Skin Syndrome. This is the first-ever Fast Track Designation granted for this rare genetic skin disease, which currently has no approved treatments. The company expects to initiate a Phase 2/3 clinical study for the indication in the second half of 2026.